Loading clinical trials...
Loading clinical trials...
A Randomised, Repeat-dose, Placebo-controlled, Three-way Crossover, Double Dummy Study to Evaluate and Compare the Efficacy of Fluticasone Furoate Inhalation Powder Delivered Via the Single Strip Dry Powder Inhaler When Administered Either in the Morning or in the Evening, in Male and Female Asthmatic Subjects
Conditions
Interventions
Fluticasone Furoate (FF)
Placebo
Locations
1
Australia
GSK Investigational Site
Randwick, New South Wales, Australia
Start Date
March 1, 2013
Primary Completion Date
March 1, 2014
Completion Date
March 1, 2014
Last Updated
January 9, 2017
NCT02327897
NCT07486401
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions